ArticleAmerican journal of translational research2025
Comprehensive evaluation of combined AngioJet and drug-coated balloon therapy for diabetic foot ulcers with lower extremity arterial occlusive disease.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of AngioJet mechanical thrombectomy combined with drug-coated balloon (DCB) therapy in patients with lower extremity arterial occlusive disease (ASO) and diabetic foot ulcers (DFU), focusing on its effects on hemodynamics, glycemic control, inflammatory markers, and one-year ulcer recurrence.
methodsThis retrospective study involved 198 patients with ASO and DFU treated between April 2021 and March 2024. Of these, 104 received combined AngioJet and DCB therapy (combined group), while 94 underwent mechanical thrombectomy alone (control group). Clinical outcomes, hemodynamic parameters, blood glucose levels, inflammatory markers, and functional scores were assessed before and after treatment. Ulcer recurrence was evaluated during a one-year follow-up period.
resultsThe combined group exhibited significantly better clinical outcomes and greater improvements in hemodynamics (pulse index and resistive index), glycemic control (fasting/postprandial glucose and HbA1c), and inflammatory markers (CRP, TNF-α, IL-6) compared to the control group. Functional indicators, including the ankle-brachial index, Rutherford and Wagner grades, and claudication distance, improved more in the combined group. The one-year recurrence rate was significantly lower in the combined group.
conclusionThe combined AngioJet-DCB approach demonstrates enhanced clinical efficacy in the management of ASO-DFU by improving hemodynamic outcomes and reducing the risk of ulcer recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.